Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019
Albany, NewYork (PRWEB) January 28, 2014
GBI Research, the leading business intelligence provider, has released its latest research, "Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 – Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need", which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia.
Click Here Read The Complete Report: http://www.researchmoz.us/gastrointestinal-therapeutics-in-asia-pacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-high-regional-unmet-need-report.html.
The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.
Disease overview and treatment usage patterns
Market size and forecast for IBS, UC and CD in APAC market from 2012 to 2019
Major marketed products for the indications types covered
In-depth pipeline analysis for IBS, UC and CD
Key drivers and restraints that have had and are expected to have a significant impact upon the market
Key licensing and co-development agreements in the gastrointestinal therapeutics market
Browse All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html.
Reasons to Buy
The report will enhance your decision-making capability by allowing you to:
Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
All Countrywise Report @ http://www.researchmoz.us/country.html.
List of Figures
Figure 1: Gastrointestinal Therapeutics Market, Treatment Algorithm of Ulcerative Colitis, 2007
Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza 2006–2012
Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira 2006–2012
Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade 2006–2012
Table 5: Gastrointestinal Therapeutics Market, Difference Between Ulcerative Colitis and Crohn’s Disease, 2007
Table 6: Gastrointestinal Therapeutics Market, Treatment Options of Ulcerative Colitis, 2011
Table 7: Gastrointestinal Therapeutics Market, Classification of Crohn’s Disease, 2013
Antibody-Drug Conjugates 2014
The report (http://www.researchmoz.us/antibody-drug-conjugates-2014-a-business-technology-and-pipeline-analysis-report.html) entitled "Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis" published in January 2014 is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs.The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms.
Advances in the Rheumatoid Arthritis Market
In 2012, (http://www.researchmoz.us/advances-in-the-rheumatoid-arthritis-market-report.html) immunology drugs generated global sales of around US$36.6bn of which two thirds were associated with the management rheumatology related conditions (US$24.5bn), the remainder of sales were split evenly between the treatment of dermatological and gastroenterology related conditions. Revenues growth has been driven by improvements in diagnosis and early, more aggressive treatment of RA, the approval of new disease modifying anti rheumatic drugs (DMARDs), new formulations/devices and line extensions.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. Researchmoz fulfill all your research needs spanning across industry verticals with huge collection of market research reports.Researchmoz provide services to all sizes of organizations and across all industry verticals and markets.Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving unbiased and deep insights on which reports will satisfy your needs at the best price.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948